To further explore the efficacy of bortezomib and WEE1 inhibitor in the primary patient’s sample, we treated the leukemic cells of a patient newly diagnosed with T-ALL with bortezomib for 24 and 72 h. This evidence concerns the gene WEE1 and acute lymphoblastic leukemia.